However, when CD63 antibody and MB-21 were added to the cancer EVs, followed by flow cytometric analysis, the CD63 positive EVs increased to 19.2%, while the miR-21 positive EVs among cancer EVs increased to 30.2%. The gene discussed is CD63; the disease is cancer.